Airway Closure During Extracorporeal Membrane Oxygenation: The AiCLOSE Study

Last updated: May 8, 2024
Sponsor: Lorenzo delSorbo
Overall Status: Active - Recruiting

Phase

N/A

Condition

Respiratory Failure

Lung Injury

Acute Respiratory Distress Syndrome (Ards)

Treatment

Acute hypoxemic respiratory failure patients on VV-ECMO

Clinical Study ID

NCT05196074
21-5784
  • All Genders

Study Summary

About 65,000 Canadians develop acute respiratory failure requiring breathing machines (ventilators) to give oxygen to their lungs. Unfortunately, up to 50% of these individuals will not survive their illness.

Mechanical ventilation through breathing machines, though potentially lifesaving, may further injure the lungs and the respiratory muscles. In the patients with the most severe and life threatening forms of respiratory failure a breathing machine alone may not be able to provide enough oxygen to the lungs and vital organs. In these critical situations, patients may require an artificial lung machine, which is referred to as extracorporeal membrane oxygenation (ECMO) to temporarily replace the function of the patient's own lung and supply critical oxygen to the body, while protecting the damaged lungs. How to use the breathing machine safely while a patient is on ECMO is still unknown. Using conventional breathing machine settings while on ECMO can lead to large portions of the lungs or airway to remain collapsed, which can contribute to further lung damage.

The investigators have recently discovered a way of detecting if patients on a breathing machine suffer from collapsed airways. Knowing if the most severe patients on ECMO have airway collapse is a pivotal question that the investigators plan to answer in our study. The investigators will use our technique to determine how many patients on ECMO have airway closure and determine if this contributes to a longer time on ECMO and a longer time on a breathing machine, and if this impacts a patient's survival in the intensive care unit.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Acute hypoxemic respiratory failure
  • VV-ECMO
  • Less than 24 hours from ECMO cannulation

Exclusion

Exclusion Criteria:

  • Air leak
  • VV-ECMO as bridge to lung transplantation
  • Status asthmaticus

Study Design

Total Participants: 299
Treatment Group(s): 1
Primary Treatment: Acute hypoxemic respiratory failure patients on VV-ECMO
Phase:
Study Start date:
April 04, 2022
Estimated Completion Date:
April 30, 2026

Connect with a study center

  • Toronto General Hospital

    Toronto, Ontario M5G 2N2
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.